U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H26N2O4
Molecular Weight 274.3565
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TYBAMATE

SMILES

CCCCNC(=O)OCC(C)(CCC)COC(N)=O

InChI

InChIKey=PRBORDFJHHAISJ-UHFFFAOYSA-N
InChI=1S/C13H26N2O4/c1-4-6-8-15-12(17)19-10-13(3,7-5-2)9-18-11(14)16/h4-10H2,1-3H3,(H2,14,16)(H,15,17)

HIDE SMILES / InChI

Description

Tybamate is a minor tranquilizer that is chemically and pharmacologically related to meprobamate. It is useful in treating anxiety and tension associated with psychoneurotic disorders.

CNS Activity

Originator

Approval Year

1965
171
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Solacen

Approved Use

Anxiolytic

Launch Date

-1.57766402E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10 μg/mL
EXPERIMENT
https://www.sciencedirect.com/science/article/pii/S0099542808600258
15 mg/kg single, oral
dose: 15 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TYBAMATE serum
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
EXPERIMENT
https://www.sciencedirect.com/science/article/pii/S0099542808600258
15 mg/kg single, oral
dose: 15 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TYBAMATE serum
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
350 mg 4 times / day steady, oral
Highest studied dose
Dose: 350 mg, 4 times / day
Route: oral
Route: steady
Dose: 350 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
unhealthy, 22 - 41 years
Health Status: unhealthy
Condition: psychosomatic symptoms in infertility patients
Age Group: 22 - 41 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
unhealthy, 22 - 41 years
n = 17
Health Status: unhealthy
Condition: psychosomatic symptoms in infertility patients
Age Group: 22 - 41 years
Sex: F
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
Other AEs: Drowsiness, Dizziness...
Other AEs:
Drowsiness (7 patients)
Dizziness (6 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
750 mg 4 times / day steady, oral
Highest studied dose
Dose: 750 mg, 4 times / day
Route: oral
Route: steady
Dose: 750 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14138831/
unhealthy, 49.5 years
n = 66
Health Status: unhealthy
Condition: anxious neurotic
Age Group: 49.5 years
Sex: M+F
Population Size: 66
Sources:
https://pubmed.ncbi.nlm.nih.gov/14138831/
Other AEs: Tachycardia, Dry mouth...
Other AEs:
Tachycardia (1 patient)
Dry mouth (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/14138831/
AEs

AEs

AESignificanceDosePopulation
Dizziness 6 patients
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
unhealthy, 22 - 41 years
n = 17
Health Status: unhealthy
Condition: psychosomatic symptoms in infertility patients
Age Group: 22 - 41 years
Sex: F
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
Drowsiness 7 patients
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
unhealthy, 22 - 41 years
n = 17
Health Status: unhealthy
Condition: psychosomatic symptoms in infertility patients
Age Group: 22 - 41 years
Sex: F
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
Dry mouth 1 patient
750 mg 4 times / day steady, oral
Highest studied dose
Dose: 750 mg, 4 times / day
Route: oral
Route: steady
Dose: 750 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14138831/
unhealthy, 49.5 years
n = 66
Health Status: unhealthy
Condition: anxious neurotic
Age Group: 49.5 years
Sex: M+F
Population Size: 66
Sources:
https://pubmed.ncbi.nlm.nih.gov/14138831/
Tachycardia 1 patient
750 mg 4 times / day steady, oral
Highest studied dose
Dose: 750 mg, 4 times / day
Route: oral
Route: steady
Dose: 750 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14138831/
unhealthy, 49.5 years
n = 66
Health Status: unhealthy
Condition: anxious neurotic
Age Group: 49.5 years
Sex: M+F
Population Size: 66
Sources:
https://pubmed.ncbi.nlm.nih.gov/14138831/
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY554377
https://www.001chemical.com/chem/4268-36-4
ABI Chem
AC1L2FWM
Ambinter
Amb22734893
http://www.ambinter.com/reference/22734893
Aurora Fine Chemicals LLC
A17.944.630
http://online.aurorafinechemicals.com/info?ID=A17.944.630
BOC Sciences
4268-36-4
ChemMol
99094824
http://www.chemmol.com/chemmol/99094824.html
Chemieliva Pharmaceutical Co., Ltd
PBCM1305851
Compound Cloud
20266
HongKong Chemhere
SCA31878
LGC Standards
LGCFOR1626.00
https://www.lgcstandards.com/US/en/p/LGCFOR1626.00
Molcore
MC554377
https://www.molcore.com/product/4268-36-4
NCI Plated 2007
172126
NovoSeek
20266
Sigma Aldrich
PH003059
Sigma Aldrich
PH003059|ALDRICH
Sigma-Aldrich
PH003059_ALDRICH
https://www.sigmaaldrich.com/catalog/product/aldrich/ph003059
Smolecule
S546095
http://www.smolecule.com/products/s546095
THE BioTek
bt-284464
https://www.thebiotek.com/product/inhibitors/bt-284464
ZINC
ZINC000001692922
http://zinc15.docking.org/substances/ZINC000001692922
ZINC
ZINC000002037958
http://zinc15.docking.org/substances/ZINC000002037958
PubMed

PubMed

TitleDatePubMed
Evaluation of a new minor tranquilizer: tybamate (Solacen).
1965 Dec 6
Solacen-tybamate.
1966 Dec

Sample Use Guides

In Vivo Use Guide
The usual dose for adults is 0.75 to 2 gm per day. Daily doses larger than 3 gm should not be used.
Route of Administration: Oral
Name Type Language
TYBAMATE
HSDB   INN   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
W 713
Code English
Tybamate [WHO-DD]
Common Name English
2-(Hydroxymethyl)-2-methylpentyl butylcarbamate carbamate
Systematic Name English
TYBAMATE [HSDB]
Common Name English
SOLACEN
Brand Name English
TYBAMATE [MI]
Common Name English
W-713
Code English
NSC-172126
Code English
CARBAMIC ACID, BUTYL-, 2-(((AMINOCARBONYL)OXY)METHYL)-2-METHYLPENTYL ESTER
Common Name English
TYBAMATE [USAN]
Common Name English
tybamate [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29756
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
Code System Code Type Description
DRUG CENTRAL
2783
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY
HSDB
3410
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY
RXCUI
62178
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY RxNorm
WIKIPEDIA
Tybamate
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY
INN
1721
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY
ChEMBL
CHEMBL2104816
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY
NSC
172126
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY
NCI_THESAURUS
C98240
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY
EPA CompTox
DTXSID7023728
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY
SMS_ID
100000076637
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY
EVMPD
SUB11369MIG
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY
ECHA (EC/EINECS)
224-254-9
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY
CAS
4268-36-4
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY
MESH
C100147
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY
PUBCHEM
20266
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY
MERCK INDEX
m11280
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY Merck Index
FDA UNII
3875LLL8M8
Created by admin on Fri Dec 15 15:36:01 UTC 2023 , Edited by admin on Fri Dec 15 15:36:01 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of TYBAMATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966